

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number  
**WO 2005/016122 A3**

(51) International Patent Classification<sup>7</sup>: G01N 33/00,  
A01K 67/00, 67/027

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/US2004/026052

(22) International Filing Date: 11 August 2004 (11.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/494,197 11 August 2003 (11.08.2003) US  
60/481,952 26 January 2004 (26.01.2004) US

(71) Applicants (for all designated States except US): **CHILDREN'S HOSPITAL MEDICAL CENTER** [US/US]; 3333 Burnet Avenue, Cincinnati, OH 45229 (US). **UNIVERSITY OF CINCINNATI** [US/US]; 2624 Clifton Avenue, Cincinnati, OH 45221-0623 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRUNSKILL, Eric, W.** [US/US]; 6477 Chablis Drive, Cincinnati, OH 45011 (US). **POTTER, S., Steven** [US/US]; 6983 Treeridge Drive, Cincinnati, OH 45244 (US).

(74) Agents: **NESBITT, Daniel, F.** et al.; Hasse & Nesbitt LLC, 7550 Central Parke Blvd., Mason, OH 45040 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

**Published:**

— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
2 June 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NPAS3 MUTANT MICE AND USES FOR SCREENING AND TESTING THERAPIES FOR SCHIZOPHRENIA AND RELATED NEUROLOGICAL DISORDERS

(57) Abstract: A transgenic mouse with a gene-targeted mutation of the *Npas3* gene, and a model of schizophrenia and related neurological disorders such as Obsessive-Compulsive Disorder, Tourette's Syndrome, and bipolar disorders, and other neurological disorders affecting locomotor activity, including Parkinson's Disease. A method is also provided for use of the *Npas3*-deficient mouse for testing the efficacy of a biologically active agent as a treatment for schizophrenia and related neurological disorders. The methods further includes uses of cells and cell lines derived from an *Npas3*-deficient mouse to screen biologically active agents that can alter biochemical pathways involved in schizophrenia and related neurological disorders, including those affecting locomotion.



WO 2005/016122 A3